TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• TP53 mutations are frequent in cancer, contributing to therapy resistance by inhibiting apoptosis.
• p53-mutant tumors exhibit resistance to various immune-based therapies, including checkpoint inhibitors, CAR T-cell therapy, and HSCT.
• p53 mutations play a critical role in tumor cells' ability to evade immune surveillance.

Purpose of the Study:

• To review mechanisms of immune evasion by p53-mutant tumors.
• To explore how p53 mutations alter the tumor microenvironment (TME) and promote immunosuppression.
• To discuss clinical evidence and therapeutic strategies for p53-mutant cancers.

Main Methods:

• Literature review of recent studies on p53 mutations and immune evasion.
• Analysis of mechanisms by which p53-mutant tumors evade T cells, NK cells, and macrophages.
• Examination of TME modulation by p53-mutant cells and their effects on bystander cells.

Main Results:

• p53-mutant tumors employ diverse strategies to evade immune surveillance from key immune cells.
• These tumors actively reshape the TME, recruiting and reprogramming cells like macrophages and regulatory T cells to create an immunosuppressive environment.
• Clinical data supports the association between p53 alterations and immune evasion in various cancers.

Conclusions:

• p53 mutations are central drivers of immune evasion in cancer, impacting multiple facets of the anti-tumor immune response.
• Understanding these mechanisms is crucial for developing effective immunotherapies for p53-mutant cancers.
• Targeting immune evasion pathways in p53-mutant tumors holds promise for improving patient outcomes.